Abstract

The present work aims to develop and characterize the controlled release of Methylphenidate matrix tablets used for the treatment of attention deficit hyperactivity disorder (ADHD). Development of CR Methylphenidate is proposed considering the adverse event profile and high fluctuation index of Methylphenidate observed with IR dosage forms. In the present work, attempts were made to formulate and evaluate the controlled release of matrix tablets of Methylphenidate. Methylphenidate was subjected to preformulation studies; based on the results obtained Methylphenidate controlled-release tablets were successfully formulated. Formulations prepared by direct compression technique. Set of trials were formulated for which Methylphenidate evaluated parameters (bulk density, tapped density, compressibility index, hausner’s ratio, weight, thickness, hardness) was found to lie within the specifications. Dissolution study was performed in USP type II apparatus at 100 RPM in pH 6.8 phosphate buffer. From the results of the in vitro study it appears that the release of the Methylphenidate was significantly influenced by the characteristics of the polymer used.